LabCorp(R) Now Offering UGT1A1 Pharmacogenetic Test for Dosing Colorectal Cancer Therapy

Rights to Test for UGT1A1 Mutations Associated with Serious Adverse Reaction to Irinotecan Hydrochloride Sublicensed from Mayo Foundation BURLINGTON, N.C., Feb. 13 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced the availability of a

LabCorp To Present At The UBS Global Healthcare Services Conference

BURLINGTON, N.C., Feb. 10 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, are

LabCorp(R) Licenses the Signature Genetics(TM) Pharmacogenetic Interpretation and Reporting Service

Proprietary Service Helps Physicians Use CYP450 Information to Customize Medications for Optimal Patient Treatment BURLINGTON, N.C., Jan. 23 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that it has licensed a drug response

Dr. Leroy E. Hood and LabCorp(R) Establish Collaborative Relationship

BURLINGTON, N.C., Jan. 9 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that it has entered into a strategic consulting relationship with world renowned molecular biologist Leroy E. Hood, M.D., Ph.D. The collaboration will combine Dr.

LabCorp To Present at the JPMorgan Healthcare Conference

BURLINGTON, N.C., Jan. 9 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled

LabCorp(R) Prices $250 Million in Senior Notes Due 2015

BURLINGTON, N.C., Dec. 9 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that it has priced its $250 million aggregate principal amount of Senior Notes due 2015, pursuant to LabCorp's new shelf registration statement.

LabCorp(R) Announces Proposed Sale of $250 Million in Senior Notes Due 2015

BURLINGTON, N.C., Dec. 8 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that it plans to sell up to $250 million aggregate principal amount of Senior Notes due 2015, pursuant LabCorp's new shelf registration statement.

LabCorp(R) Announces Board Authorization of $500 Million Stock Repurchase Program

Company To Purchase $250 Million Under Overnight Share Repurchase Agreement as Part of Program BURLINGTON, N.C., Dec. 7 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that its Board of Directors has authorized an additional stock

ViroMed Introduces Molecular Tests for Rapid Diagnosis of Respiratory Viruses Including Avian Flu

Real-time PCR Test Quickly Detects and Differentiates the H5N1 Avian Flu Strain from Other More Common Respiratory Virus Strains BURLINGTON, N.C. and MINNEAPOLIS, Dec 01, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ViroMed Laboratories, Inc., a subsidiary of Laboratory Corporation of

Laboratory Corporation of America(R) Holdings Announces Appointment of David P. King as Chief Operating Officer

BURLINGTON, N.C., Nov 30, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that its Chief Operating Officer, Richard L. Novak has decided to retire on December 31, 2006. LabCorp also announced that Mr.